Detalhe da pesquisa
1.
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.
Cell
; 171(3): 540-556.e25, 2017 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-28988769
2.
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.
Cell
; 174(4): 1033, 2018 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30096301
3.
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
BJU Int
; 133(2): 214-222, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37803523
4.
Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis.
Br J Cancer
; 127(2): 313-320, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35449454
5.
Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.
J Urol
; 207(3): 541-550, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34643090
6.
A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging.
J Urol
; 204(2): 239-246, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32074006
7.
Correction to: Genomic Subtyping in Bladder Cancer.
Curr Urol Rep
; 21(7): 25, 2020 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32409908
8.
Genomic Subtyping in Bladder Cancer.
Curr Urol Rep
; 21(2): 9, 2020 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32166460
9.
Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
Int J Cancer
; 145(12): 3453-3461, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31125117
10.
Recurrent tumor-specific regulation of alternative polyadenylation of cancer-related genes.
BMC Genomics
; 19(1): 536, 2018 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30005633
11.
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.
Genome Res
; 24(5): 743-50, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24782321
12.
APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner.
Gynecol Oncol
; 147(3): 663-671, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29079036
14.
Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
Urol Oncol
; 42(6): 177.e5-177.e14, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38480079
15.
Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel.
Clin Genitourin Cancer
; 22(4): 102091, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38735133
16.
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
Clin Cancer Res
; 29(24): 5116-5127, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870965
17.
Aberrant expression of long noncoding RNAs in cervical intraepithelial neoplasia.
Int J Gynecol Cancer
; 22(9): 1557-63, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23095774
18.
Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy.
Urol Oncol
; 40(7): 287-294, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30528886
19.
Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma.
Virchows Arch
; 481(3): 397-403, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35612672
20.
Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial.
Clin Cancer Res
; 28(23): 5107-5114, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36190522